Shots: OXB to receive $4.83M as an option exercise fee & ~$37.96M in development, regulatory & sales milestones along with royalty on sales of a CF gene therapy product under […]readmore
Tags : License
Shots: Evotec receives $20M as an option fee & is eligible to receive ~$250M as milestones along with royalties. BMS will be responsible for further development & commercialization of a […]readmore
Shots: Pharmapark to get exclusive rights to commercialize HD204 and is responsible for local registration, sales, and marketing of the biosimilar in Russia in collaboration with Russian import substitution strategy […]readmore
Shots: Bio-Thera to receive $30M up front following the achievement of P-III satisfactory results and is eligible for commercial milestones along with royalties. The transaction is expected to close in […]readmore
Shots: Sanofi to receive ~$353M including $2.25M up front and remaining as development, regulatory and commercial milestones as well as royalties on WW net sales of programs GBT gets exclusive […]readmore
Shots: The companies signed an exclusive license agreement to develop COVISHIELD + two mAb cocktail against emerging variants of SARS-CoV-2 including UK (B.1.1.7), South Africa (B.1.351), and Japan/Brazil (B.1.128) variants […]readmore
Shots: WuXi Bio to receive up front and is eligible for development & commercialization milestones, along with royalties on sales of any potential products commercialized from the panel Exelixis get […]readmore
Shots: Merck KGaA to receive up front, additional regulatory, approval, and sales milestone along with royalties on sales of pimasertib and MSC2015103B. The agreement broadens Day One’s clinical-stage pipeline of […]readmore
Shots: Beijing Tide to receive up to $517.5M including up front, development, regulatory and sales milestone along with royalties and an option for a revenue-sharing arrangement for certain developed products […]readmore
Shots: Biomunex to receive up front, development, regulatory & sales milestones, equity investment along with royalties on sales of therapies Onward get the right to pursue development, manufacture & commercialize […]readmore